GOLDCUP 34064 AB Goldcup 34064 AB Announces Vironova BioAnalytics Acquired by Investor Group

Transparency directive : regulatory news

20/11/2023 19:50

Vironova BioAnalytics AB Acquired by an investor syndicate, led by Quatre Lab, to expand its TEM services for the pharmaceutical industry; to be rebranded as QuTEM

STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2023 / Vironova BioAnalytics, a leading provider of transmission electron microscopy (TEM) services, is pleased to announce its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the participation of Accord Investment Partners and Venture Targeter AB. This strategic move will enable Vironova BioAnalytics to enhance its capabilities and continue to deliver TEM analyses according to Good Manufacturing Practices (GMP) for the pharmaceutical industry. Following the completion of the acquisition, the company will be renamed and rebranded as QuTEM.

Vironova BioAnalytics has established a strong reputation as a trusted partner for pharmaceutical companies globally, known for its commitment to high-quality standards. This acquisition represents an important step in the company's growth journey, fostering opportunities for innovation and expansion. The strategic decision to rebrand the company as QuTEM reflects the commitment to evolving and delivering cutting-edge TEM solutions to meet the evolving quality control needs of the pharmaceutical sector.

The partnership with Columbus Venture Partners through Quatre Lab, Accord Investment Partners and Venture Targeter AB brings together valuable experience and new resources. This collaboration will empower QuTEM to expand its services, invest in advanced technologies, and accelerate development efforts. The company will maintain its focus on providing GMP-compliant TEM analyses crucial for pharmaceutical research, development, and quality control.

Josefina Nilsson, CEO of QuTEM (formerly Vironova BioAnalytics), expressed enthusiasm for the acquisition, saying, "We are excited to join forces with these new partners to allow us to provide the pharmaceutical industry with top-quality TEM services, and to expand our capabilities, drive innovation and better serve our clients."

Javier García, co-founder and general partner of Columbus Venture Partners, also expressed his excitement about this acquisition. "Vironova BioAnalytics has a strong track record of delivering precise and reliable TEM analyses. We see potential in this collaboration and are committed to supporting the company's growth and mission in the pharmaceutical sector."

This acquisition and rebranding mark an inspiring new chapter for QuTEM. The company's experienced team will continue to provide pharmaceutical clients with valuable insights and data to advance their drug development and quality assurance efforts. The company, alongside its new partners, is poised to drive innovation and make significant contributions to the pharmaceutical industry. Clients can expect a seamless transition, with QuTEM continuing to deliver the same level of excellence and reliability they have come to rely on from Vironova BioAnalytics.

For more information about QuTEM (formerly Vironova BioAnalytics) and its TEM services, please visit qutem.com.
Contact information:
Josefina Nilsson
+46 76 109 01 91

About QuTEM

QuTEM offers market leading and unique analysis to researchers, developers, and manufacturers of advanced therapeutics. QuTEM is starting with an impressive range of clients across academia, SME biopharma companies, big pharma, CDMOs and QA specialists. With a commitment to quality and precision, the company supports pharmaceutical companies in their research, development, and quality control efforts.

QuTEM's unique capabilities include:

- Highly accurate determination of capsid size distribution, going far beyond full/empty analysis and providing highly accurate measurements of capsid content down to numbers of kilobase pairs.

- Offer an extensive service portfolio including a wide range of analyses e.g., AAVs, adenoviral vectors, lentivirus, VLPs, LNPs, liposomes., etc. to support biopharma needs.

- GMP compliance; QuTEM's predecessor company was the only globally GMP certified provider of these services and all workflows, software and data handling is performed in with full GMP compliance.

For more information, visit qutem.com.

About Vironova BioAnalytics:
Vironova BioAnalytics is a leading provider of transmission electron microscopy (TEM) services, specializing in delivering GMP-compliant TEM analyses for the pharmaceutical industry.

About Quatre Lab:
Quatre Lab is a Contract Research Organization (CRO) based in San Sebastian (Spain) engaged, among others, on the practice of quality control tests analysis for Advanced Therapy Medicinal Products (ATMPs) and related services to pharmaceutical, biotechnology, and other companies involved in pharmaceutical, biotechnology and medicinal product research, development, manufacturing and/or commercialization.

About Columbus Venture Partners:
Columbus Venture Partners is a Spanish venture capital management company that brings a unique approach to investing in outstanding opportunities across all stages of (bio) pharmaceutical drug development and advanced biopharmaceutical manufacturing technologies. The company manages over $250 million across its three funds and has built an impressive track record of performance with recently successful exits in Viralgen, Askbio, PTS, Sanifit, or Recovid, among others. The Columbus professional team combines solid scientific, medical, and business knowledge with extensive experience in the field of biotechnology entrepreneurship. For more information, please visit www.columbusvp.com.

About Accord Investment Partners:
Accord Partners is a UK based investment firm, founded in 2020 by Sam Breuning. Accord focuses on backing ambitious management teams, with capital and support to enable them to take their businesses to the next level. Accord's other investment in the pharmaceutical sector is the Contained Air Solutions, which it is growing organically and through acquisitions into a globally focused business across containment, automation, and advanced therapeutics.

About Venture Targeter AB:
Venture Targeter AB is a Swedish investment company with a strategic focus on special situation investments. It is owned and operated by business angels, entrepreneurs and Katalysen Ventures AB, a notable player in the investment space.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Goldcup 34064 AB

View source version on accesswire.com:

GOLDCUP 34064 AB's latest news

20/11/2023 19:50

Other stories

19/07/2024 21:32
19/07/2024 19:34
19/07/2024 11:21
19/07/2024 18:12
19/07/2024 19:30
19/07/2024 13:49
19/07/2024 19:51
19/07/2024 19:34
19/07/2024 13:42
19/07/2024 18:28
19/07/2024 23:31
19/07/2024 22:17
19/07/2024 21:02
19/07/2024 06:52
19/07/2024 23:01
20/07/2024 01:07
19/07/2024 18:48
19/07/2024 13:37
19/07/2024 15:48
18/07/2024 12:43
19/07/2024 19:55
19/07/2024 16:48
19/07/2024 16:05
19/07/2024 09:20
19/07/2024 20:17
19/07/2024 21:47
19/07/2024 23:40
19/07/2024 21:13
19/07/2024 23:22
19/07/2024 17:53
18/07/2024 12:52
19/07/2024 12:08
19/07/2024 20:15
19/07/2024 15:54
19/07/2024 14:23
18/07/2024 10:59
19/07/2024 18:51
18/07/2024 18:05